Abridge’s last reported valuation is $5.3 billion, set in its June 2025 Series E. The healthcare AI company, founded in 2018 by cardiologist Shiv Rao, listens to doctor-patient conversations and drafts the clinical note. It is live at more than 300 US health systems and supports more than 100 million conversations a year, the company said in June 2026.
Abridge at a glance
Question | Answer | As of |
|---|---|---|
Who owns Abridge? | It is private, held by its founders, staff and investors including a16z, Lightspeed, IVP, Elad Gil, Spark Capital and Union Square Ventures | Nov 2026 |
Valuation | $5.3 billion (reported) | Jun 2025 |
Funding | About $773 million in announced rounds; press reports say about $830 million | Jun 2026 |
Revenue | Not disclosed; $117 million in contracted ARR reported | Q1 2025 |
Customers | More than 300 US health systems | Nov 2026 |
Scale | More than 100 million conversations a year | Jun 2026 |
Employees | 435 | Apr 2026 |
CEO | Shiv Rao, MD, co-founder | Nov 2026 |
Founded | February 2018, by Shiv Rao and Sandeep Konam | 2018 |
Headquarters | San Francisco, with a hub in New York and roots in Pittsburgh | Nov 2026 |
Legal entity | Abridge AI, Inc., a Delaware corporation | Nov 2026 |
Website | abridge.com | 2026 |
What does Abridge do?
Abridge records the conversation between a clinician and a patient, with AI drafting the note inside the electronic health record for the clinician to review. It began there and now sells a wider platform to hospitals, which it calls clinician intelligence:
Clinical documentation: notes across specialties and languages, for doctors and, since a 2024 project with Mayo Clinic and Epic, nurses
Revenue cycle: billing and risk-adjustment codes captured during the visit, real-time prior authorization with Highmark and Availity, and pre-bill review of inpatient claims since September 2026
Abridge Assistant: clinical decision support since April 2026, drawing on NEJM and JAMA, and on Cochrane evidence through a Wiley deal of November 16, 2026
Care Signals, debuted with Kaiser Permanente in August 2026
Clinical trials: surfacing trial opportunities during the visit, in partnership with Eli Lilly
Abridge doesn’t publish prices on its website; health systems buy it through enterprise agreements.
Abridge in 2026: from notes to decisions and billing
Abridge went from more than 250 health systems in February 2026 to more than 300 by June. On June 11 it launched its clinician intelligence platform, said NVIDIA would help build a foundation model for clinical conversations, and took a strategic investment from Eli Lilly.
In September the US Department of Veterans Affairs selected Abridge under an enterprise contract, through a distribution partner. The contract has a $775.72 million ceiling over five years, but it is shared across all eligible vendors, so that isn’t Abridge’s revenue. Abridge already serves clinicians at more than 75 VA medical centers. In October it signed an enterprise-wide agreement with the University of Texas System, and in November it made the Abridge Assistant free for 108,000 clinicians at community health centers.
Abridge valuation: history over time
Abridge’s valuation rose more than sixfold in 16 months, from $850 million in February 2024 to a reported $5.3 billion in June 2025. Abridge’s own Series E announcement didn’t state a valuation. No higher price has been reported since, and Eli Lilly’s 2026 investment came with no disclosed valuation.
Date | Event | Valuation |
|---|---|---|
Jun 2026 | Eli Lilly strategic investment | Not disclosed |
Jun 2025 | Series E | $5.3B (reported) |
Feb 2025 | Series D | $2.75B post-money |
Feb 2024 | Series C | $850M |
Abridge funding: how much has it raised?
About $773 million in announced rounds (our sum), counting the Series E at the $315.9 million an SEC filing shows sold; Abridge announced it as $300 million. Press reports in 2026 put the total at about $830 million. The amount of Eli Lilly’s investment isn’t disclosed.
Date | Round | Amount | Led by | Valuation |
|---|---|---|---|---|
Jun 11, 2026 | Strategic investment | Not disclosed | Eli Lilly | Not disclosed |
Jun 24, 2025 | $300M announced; $315.9M in the SEC filing | Andreessen Horowitz, with Khosla Ventures | $5.3B (reported) | |
Feb 17, 2025 | $250M | Elad Gil, IVP | $2.75B | |
Feb 23, 2024 | Series C | $150M | Lightspeed, with Redpoint | $850M |
Oct 26, 2023 | Series B | $30M | Spark Capital | Not disclosed |
Aug 11, 2022 | Series A-1 | $12.5M | Wittington Ventures | Not disclosed |
By Oct 2020 | Seed and Series A | $15M | Union Square Ventures, UPMC | Not disclosed |
Was there a $316 million Series E extension in 2026?
Probably not as new money. Fortune and others describe a $316 million extension closed in April 2026 at the same $5.3 billion. Abridge hasn’t announced one, and its latest SEC filing, from June 2025, already shows $315.9 million sold in the original Series E. The two numbers match, so the reported extension is most likely the same money.
What is Abridge’s revenue?
Abridge doesn’t publish its revenue, and no 2026 figure has been reported. The last public number is $117 million in contracted annual recurring revenue in the first quarter of 2025, reportedly. Contracted ARR counts every signed deal, including customers who aren’t live yet, so actual revenue at that time was lower. Abridge doesn’t disclose profit or margins.
| Date | Figure | Type |
|---|---|---|
| Mar 2025 | $117M | Booked ARR |
| Oct 2024 | $50M | Booked ARR |
Abridge ARR (annual recurring revenue)
$117 million in contracted ARR in Q1 2025, reportedly. Abridge hasn’t confirmed an ARR figure, and customers have roughly doubled since then, from more than 150 health systems in June 2025 to more than 300 in June 2026.
Abridge MRR (monthly recurring revenue)
Abridge doesn’t publish MRR. $117 million in contracted ARR works out to about $9.75 million a month (our calculation), as of Q1 2025.
Who owns Abridge?
Abridge is private. It is held by its founders, employees and investors, and none of their stakes are public. Andreessen Horowitz led the latest priced round. Other backers include Khosla Ventures, Elad Gil, IVP, Lightspeed, Redpoint, Spark Capital, Union Square Ventures, Bessemer, CapitalG, NVIDIA’s NVentures and Wittington Ventures, plus healthcare investors CVS Health Ventures, Kaiser Permanente Ventures, Mayo Clinic, UPMC and Eli Lilly.
Its June 2025 SEC filing lists four directors: Shiv Rao, Andy Weissman of Union Square Ventures, Will Reed of Spark Capital and Sebastian Duesterhoeft of Lightspeed. Rao said in May 2026 that an IPO isn’t on his radar.
Abridge customers: which health systems use it?
More than 300 US health systems, from the largest academic centers to community health centers. Some of the biggest deals:
Customer | What was announced | Date |
|---|---|---|
University of Texas System | Enterprise-wide agreement | Oct 8, 2026 |
US Department of Veterans Affairs | Selected under the VA enterprise contract; live at 75+ medical centers | Sep 22, 2026 |
WashU Medicine and BJC Health | Expanded to 4,000 clinicians | Sep 2, 2026 |
Northwestern Medicine | Enterprise-wide, all hospitals and care settings | Jun 11, 2026 |
UPMC | Enterprise-wide, more than 12,000 clinicians by 2026 | Oct 16, 2025 |
Northwell Health | System-wide across 28 hospitals | Oct 14, 2025 |
Kaiser Permanente | Enterprise deployment; its evaluation was published in NEJM AI | Apr 2, 2025 |
Mayo Clinic | Enterprise-wide, starting with about 2,000 clinicians | Jan 14, 2025 |
Johns Hopkins Medicine | 6,700 clinicians, six hospitals | Dec 18, 2024 |
KLAS, which rates healthcare software from customer interviews, ranked Abridge first for ambient AI in revenue cycle management for the second year running in February 2026.
Abridge competitors
The biggest threat is Epic, the health-records vendor Abridge plugs into. Abridge became the first partner in Epic’s Pals program in August 2023, but in February 2026 Epic released its own AI Charting tool, built into the record.
Rival | What it is | Latest dated fact |
|---|---|---|
Epic | Health-records giant with built-in AI Charting | Released Feb 2026 |
Microsoft | Owns Nuance and DAX Copilot; the enterprise incumbent | Bought Nuance for $19.7B in 2022 |
Ambience Healthcare | AI documentation and coding | $243M Series C at $1.25B, Jul 2025 |
Suki | Ambient AI documentation | $90M Series E, Oct 2026 |
Nabla | Clinical AI assistant, 130+ healthcare organizations | $70M Series C, Jun 2025; $120M raised in all |
OpenEvidence | Free AI search engine for doctors | A rival since Abridge added decision support in Apr 2026 |
Abridge lawsuits and privacy questions
Patients have sued Abridge customers in California, saying visits were recorded without consent. A proposed class action against Sharp HealthCare, filed on November 26, 2025, also claims Abridge inserted statements into charts saying patients had consented when they hadn’t. A second, filed on April 8, 2026 in federal court, targets Sutter Health and MemorialCare. These are allegations against the health systems, and we found no ruling in either case as of November 2026.
Who is the CEO of Abridge? Founders and leadership
Shiv Rao, MD, a practicing cardiologist at UPMC, is co-founder and CEO. He started Abridge in February 2018 with Sandeep Konam, a Carnegie Mellon robotics graduate who was its CTO at launch. Florian Metze, then a Carnegie Mellon research professor, is also credited as a co-founder and left in 2019.
Person | Role |
|---|---|
Shiv Rao, MD | Co-founder and CEO; practicing cardiologist at UPMC |
San Oo | Named chief technology officer in May 2026; previously at Slack and Notion |
Sagar Sanghvi | Named Abridge’s first chief financial officer in January 2025 |
Zachary Lipton | Joined as chief scientific officer in February 2023 from Carnegie Mellon and Amazon AI |
Tim Hwang | Named general counsel in August 2024 |
Tina Shah, MD | Named chief clinical officer in September 2023 |
Rao’s bio and contact routes: Abridge CEO Shiv Rao: email, LinkedIn and bio.
Where is Abridge based, and how many employees does it have?
San Francisco, with a second hub in New York. The company grew out of Pittsburgh, where Rao still lives and practices. Abridge had 435 employees in April 2026. Its legal entity, Abridge AI, Inc., is a Delaware corporation; its first SEC filing, in April 2018, used the earlier name intelligible.ai Inc.
Key events
Date | Event |
|---|---|
Nov 16, 2026 | Wiley deal brings Cochrane evidence to the Abridge Assistant |
Nov 13, 2026 | Assistant made free for 108,000 community health center clinicians |
Oct 8, 2026 | Enterprise-wide agreement with the University of Texas System |
Sep 22, 2026 | Selected under the VA enterprise contract |
Jun 11, 2026 | Clinician intelligence platform; Eli Lilly investment; NVIDIA model |
May 21, 2026 | San Oo named CTO |
Apr 15, 2026 | NEJM and JAMA content partnerships |
Apr 8, 2026 | Patients sue Sutter Health and MemorialCare over Abridge recordings |
Feb 2026 | Epic releases its own AI Charting tool |
Nov 26, 2025 | Proposed class action filed against Sharp HealthCare |
Jun 24, 2025 | $300M Series E, at a reported $5.3B |
Feb 17, 2025 | $250M Series D at $2.75B |
Feb 23, 2024 | $150M Series C at $850M |
Aug 16, 2023 | Becomes the first Pal in Epic’s partner program |
Aug 11, 2022 | $12.5M Series A-1 and an enterprise product for health systems |
Oct 6, 2020 | Launches publicly as an app for patients |
Feb 2018 | Founded by Shiv Rao and Sandeep Konam |
More on Abridge
Abridge CEO Shiv Rao: the cardiologist who built it
Healthcare SaaS companies: software for providers, payers and patients
List of SaaS unicorns: private software companies worth $1B or more
Harvey: another AI company built for one profession, law
Need verified CEO emails for outbound? The LeadWave AI companies email list has verified emails of the CEOs and founders of 9,000+ AI companies.







